<DOC>
	<DOC>NCT01306123</DOC>
	<brief_summary>The main purpose of this study is to assess the relative bioavailability of Nascobal Nasal Spray as compared to an IM injection of cyanocobalamin (European reference product).</brief_summary>
	<brief_title>Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration</brief_title>
	<detailed_description>This is an open-label, randomized, single-dose, two-way crossover study. The study consists of a screening visit, two 4-days confinement periods and a follow-up telephone call. The two confinement periods will be separated by a washout period of at least 28 days.</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Healthy female and male voluteers 1840 years of age BMI between 18.5 and 30.0 kg/m2 Females who are pregnant or lactating History of clinically significant metabolic, hepatic, renal, haematological, pulmondary, cardiovascular, gastrointestinal, urological, neurological or phychiatric disorders Serum vitamin B12 &lt;=250 pmol/L or MMA &gt;=0.40 umol/L Evidence of significant intranasal pathology Nasal congestion, allergic rhinitis or upper respiratory tract infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cyanocobalamin</keyword>
	<keyword>intranasal</keyword>
	<keyword>intramuscular</keyword>
</DOC>